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Abstract
This is the report of the 2nd Joint ENCCA/EuroSARC European Bone Sarcoma Network Meeting held in Leiden, The
Netherlands, on 26-27 September 2013, bringing together preclinical and clinical investigators on bone sarcoma.
The purpose of this workshop was to present the achievements of biological research and clinical trials in bone
sarcomas and to stimulate crosstalk.
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Meeting organization
The 2nd Joint ENCCA/EuroSARC European Bone Sar-
coma Network Meeting held in Leiden, The Netherlands,
on 26-27 September 2013, brought together preclinical
and clinical bone sarcoma investigators. The meeting
was organized by Stefan Bielack, representing ENCCA
(European Network for Cancer research in Children
and Adolescents, Work Package 7 (Bone sarcomas)),
Bass Hassan, representing EuroSARC (EUROpean clinical
trials in rare SARComas within an integrated translational
trial network), Anne-Marie Cleton-Jansen representing
both and Pauline de Graaf (Leiden, The Netherlands),
representing both. The purpose of this workshop was to
present the achievements and current status of biological
and translational research and clinical trials in bone sarco-
mas and to stimulate crosstalk. This manuscript is a brief
summary of the meeting, which was divided into five
sessions.
Biology/genetics: osteosarcoma
Anne-Marie Cleton-Jansen showed results of genome
wide gene expression profiling (Illumina Human-6 v2.0)
of osteosarcoma biopsies collected within the EuroBoNet
consortium. When comparing profiles from patients who
developed metastases within 5 years with those who did
not, 50% of the differentially expressed genes were macro-
phage associated thereby suggesting that macrophages
prevent metastases. This beneficial effect of tumour asso-
ciated macrophages may provide a rationale for the use of
macrophage activators such as Liposomal Muramyl-
Tripeptide-Phosphatidylethanolamine (L-MTP-PE, Mifa-
murtide). Furthermore, the Insulin-like Growth Factor 1
receptor (IGF1R) and PI3K/AKT pathways were over-
active in osteosarcoma, which in vitro could be inhibited
by the dual IR/IGF1R inhibitor Linsitinib (OSI-906) and
the Akt-inhibitor MK-2206, respectively.
Fernanda Amary presented the preliminary results of a
study on expression of fibroblast growth factor receptor,
type 1 (FGFR1) in 288 osteosarcomas. Potential bio-
markers for stratification into cohorts which may be
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candidates for treatment with selective FGFR 1-inhibitors
were discussed.
Patrick Tarpey highlighted the role of the International
Cancer Genome Consortium (ICGC) in the molecular
investigation of bone tumours. Analysis after whole gen-
ome, exome, and transcriptome sequencing revealed het-
erogeneous variations of known and new cancer genes
and pathways, including copy number changes, truncat-
ing mutations, homozygous deletions, rearrangements
and amplifications. Future work will be to establish a
dedicated panel of genes for the identification of drivers
and pathways, and analysis of the data in the clinical
context of subtypes, prognosis and potential targets for
treatment.
Ola Myklebost discussed the importance of character-
isation of tumour models in terms of tumourigenicity,
colony forming ability, proliferation and invasion/migra-
tion. The next step, as a prerequisite for personalized
treatment strategies, will be deep sequencing to screen
for genome wide gene or pathway mutations, or to detect
candidate targets. Detected targets can then be evaluated
in preclinical models, and, if successful, investigated in
second line treatment in patients with refractory disease.
Michaela Nathrath demonstrated that complex gen-
omic alterations in osteosarcoma could be analysed in
detail with different genome platforms. Using SNP6.0/
Cytoscan arrays, gains, losses and translocations in the
Myc-gene resulted in a chromothripsis-like pattern with
a poor prognostic significance. Exon sequencing of other
non-randomly distributed regions yielded 19 genes with
significantly (p = 0.01) different copy number levels, some
of which were verified by expression arrays, some of these
being potential drug targets.
Daniel Baumhoer presented information on micro-
RNA expression and TP53 alterations in osteosarcoma.
In normal tissue, TP53 inhibits the miRNA-17-92 cluster,
which regulates cellular processes as cell cycle promotion,
apoptosis, senescence and DNA repair. However, in osteo-
sarcoma, the miRNA-17-92 cluster is upregulated which
might be influenced by inactivation of TP53. Further, al-
terations in the first intron of TP53 were detected by
whole genome sequencing as a potentially osteosarcoma
specific finding.
Piero Picci discussed a revision of histopathologic classi-
fications of bone tumours from the Rizzoli bone tumour
bank. Some diagnoses (fibrosarcoma and undifferentiated
pleomorphic sarcoma) were less common after review and
others (leiomyosarcoma, synovial sarcoma, myoepithe-
lioma) were now more frequent. Also, new primary
bone tumour entities were recognized, such as myofi-
broblastic sarcoma , solitary fibrous tumour , myxofi-
brosarcoma, and others.
The immunobiology of osteosarcoma was discussed by
David Thomas. The role of IL-6, determined by the
senescence-associated secretory phenotype, was demon-
strated in an irradiated mouse model. IL-6 protects
DNA-damaged cells from malignant growth by cell cycle
arrest/senescence, whereas IL-6 deficiency results in
malignancy. This may be of importance for osteosar-
coma, as it has been shown that IL-6 levels can rise
after L-MTP-PE infusion.
Studies & new hypotheses: osteosarcoma
Matthew Sydes presented the first results of the
EURAMOS-1 (NCT00134030). Good Response (GR)
randomization, assessing pegylated interferon-α2b (ifnα).
Of 2.260 registered patients, 1.041 had a known GR and
715 of these were randomized: 358 to MAP (methotrex-
ate, adriamycin, cisplatin), and 357 to MAPifnα (MAP
followed by ifnα for 18 months). 23% patients allocated
to the MAPifnα arm did not start ifnα (main reason:
refusal); 128 patients (55%) completed ifnα, 106 (45%)
terminated early (toxicity, progression of disease, re-
fusal, other reasons) and 37 were still on treatment at
data freeze (Mar-2013). The main toxicity was haem-
atologic, grade 4 in 7% of the patients, grade 3 in 23%.
Data were presented now because the pre-specified
number of events had been reported. The hazard ratio
(HR) favoured the addition of ifnα, but the confidence
intervals (CI) were wide: HR 0.82 (0.61-1.11, 95% CI).
Three-year event-free survival (EFS) was 77% for the
MAPifnα arm vs. 74% for MAP. The conclusion was
that in rare diseases, multinational randomised con-
trolled trials are needed and feasible, and that the (pre-
liminary) estimate of primary outcome favours MAPifnα,
although without statistical significance. The CI of the HR
includes 1, and the proportion of patients that did not
start or complete ifn complicates the interpretation
[http://meetinglibrary.asco.org/content/112749-132]. Follow-
up will continue on all patients for survival.
A French osteosarcoma trial, randomising between the
addition of zoledronic acid (ZA) for 10 months to chemo-
therapy (OS2006, NCT00470223) was discussed by Lau-
rence Brugieres. The rationale to use ZA was given by
animal models. The chemotherapy backbone consists
of MTX-IFO/ETO in patients <18 and ADR/DDP/IFO-
ADR/DDP in adults >25. Post-operative chemotherapy
is adapted to histologic response and the risk group. It
is left to the discretion of the centre to use either the
MTX or ADR/DDP/IFO-ADR/DDP-based regimen in
patients between 18 and 25 years. The primary end-
point of this study is EFS; secondary endpoints are
overall survival (OS), histologic response, toxicity and
quality of life. Four hundred and seventy patients have
to be randomised to make statistically relevant conclu-
sions. Since the start of the study (April 2007), 478 patients
have been registered, and 288 have been randomised. So far
no significant ZA-related toxicity, except hypocalcaemia, has
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been reported. Extension of the study to other groups was
offered.
An Italian protocol for the treatment of localized
osteosarcoma based on P-glycoprotein (PgP) expres-
sion (ISG/OS-2, NCT01459484) was presented by Ste-
fano Ferrari. PgP-negative patients are treated with MAP
pre-and postoperatively. PgP-positive patients receive
MAP preoperatively, and GR patients continue postop-
eratively with MAP-MTP, whereas poor response (PR)
patients are treated with a high-dose IFO-based regi-
men and MTP. The study started in 2011, and 78 pa-
tients have entered the study.
In addition, Ferrari presented the interim results of the
EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.).
Here, a chemotherapy backbone of ADR, DDP and IFO -
with MTX added to preoperative chemotherapy only in
case of PR - is recommended for patients with high-grade
bone sarcomas aged 41-65 years. To date, 398 patients with
a median age of 52 years have been registered and 344 were
deemed evaluable for an interim analysis: 74% had localized
disease, the top histological diagnoses were osteosarcoma
(primary 49%, secondary 7%), and dedifferentiated chon-
drosarcoma (13%). Chemotherapy could be given according
to the recommendation in most patients and there was
only one toxic death. Neutropenia grade 4 was the most
frequently reported toxicity. Five-year OS was 55% for the
whole group and 65% with surgical remission. OS in pri-
mary and secondary osteosarcoma were similar, and poor-
est in dedifferentiated chondrosarcoma. It was concluded
that (complete) surgery is highly important in bone sar-
coma in older patients, and that the prognosis with appro-
priate therapy may not be that different from younger
patients. Furthermore, chemotherapy in this age group was
feasible, but toxic.
Interim findings from the European Relapsed Osteo-
sarcoma registry (EURELOS), a project endorsed by the
European Musculo-Skeletal Oncology Society EMSOS
and ENCCA WP7, were presented by Stefan Bielack. To
date, 470 patients with a (first) relapse after 1st line treat-
ment had been registered by three collaborating European
groups. Patient and relapse characteristics observed in this
prospective registry mirrored those of earlier retrospective
analyses, but the prospective nature of data collection also
allowed hitherto unanswered questions to be addressed,
as the contribution of routine surveillance imaging or po-
tential correlations between the use of specific agents and
outcomes. It was concluded that international collabor-
ation in relapsed OSA is feasible, but demanding, and that
this initiative may help to define standards of care. Partici-
pation will be offered to other groups after appropriate
protocol amendment.
Bass Hassan discussed the planned EuroSARC MEMOS-
study, which will use a Bayesian approach to investigate im-
munologic biomarkers in metastatic osteosarcoma. Patients
with resectable relapsed/metastatic osteosarcoma will be
evaluated on their response after 6 weeks L-MTP-PE, and
continue for 30 weeks L-MTP-PE after resection of the me-
tastases. Patients deemed unresectable will be randomised
between 6 weeks IFO with or without L-MTP-PE, will have
a biopsy of one of their lesions, and both groups will con-
tinue with IFO plus L-MTP-PE for a total duration of
30 weeks. The primary objective of the study is macro-
phage infiltration and innate immune activation in the bi-
opsy samples. The secondary objectives are to monitor the
safety, tolerability and response rate of L-MTP-PE, in terms
of progression-free and overall survival. It is aimed to open
the study in 2014.
Improving the cytotoxicity of the innate immune system
against osteosarcoma was presented as a promising ap-
proach by Marco Schilham. In vitro studies have previ-
ously shown that cetuximab can enhance NK-mediated
tumour cell killing. Furthermore, M1 and M2 macro-
phages can both be induced to inhibit growth of osteosar-
coma cells in vitro. Activation of the M1-subpopulation
with L-MTP-PE + ifnγ induces a soluble factor with anti-
tumour activity, which may be an argument in favour of
the use of macrophage activating agents as L-MTP-PE in
osteosarcoma patients. In addition, IL-10 stimulated M2-
macrophages can inhibit growth of osteosarcoma cells in
the presence of tumour specific antibodies.
Interaction: bone sarcomas
Anne-Marie Cleton-Jansen presented the achievements
of the EuroBoNeT/ENCCA-WP7 biobank (http://eurob-
onet.pathobiology.eu/cd/index.php). This web-based vir-
tual biobank has developed standard operating procedures
(SOPs) referring to uniform storage and handling of frozen
and paraffin tissue samples according to ethical guidelines.
In addition, data on cell lines, xenografts, tissue arrays and
immunohistochemical (IHC)-reagents for bone tumours
are stored. Notably, the material remains at the institute of
origin, and only parts of the material are distributed where
a request is made to the biobank. Peter Riegman illustrated
how samples could be exchanged between partners for
translational research. The sample exchange platform is
based on a closed TuBaFrost project (www.tubafrost.org),
and operates within a protected project environment. Sam-
ples or pseudonymised data can be requested via a cata-
logue or a trial locator.
Miriam Wilhelm discussed clinical aspects of osteosar-
coma in Teenagers and Young Adults (TYA). Bone sar-
comas are typical malignancies of TYAs (3%-5% of all
cancers, compared to ≤ 1% in older patients). TYA is also
a period with numerous physical, cognitive and behav-
ioural changes which may affect not only the pharmacol-
ogy of drugs. Several recent studies and meta-analyses
observed that survival probabilities for TYA with osteo-
sarcoma lagged behind that of children. Within the TYA
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cohort, females seem to have better outcomes than males.
Age and gender-specific differences in toxicity were also
observed. Miriam Wilhelm then shared information from
the EURAMOS-1 trial which showed a lack of centralisa-
tion and trial participation for the young adult population.
These data underline the need for specific care and re-
search for TYA.
Approaches to bone sarcoma research in adolescents
and young adults were presented by Dan Stark. The
complexity of care is apparent and challenging in this
age group. Both international and UK data suggest poorer
clinical outcomes of bone sarcomas in TYA than in chil-
dren or adults, including response to therapy and survival,
which is difficult to explain. Factors such as delay in diag-
nosis, poor trial recruitment, lower adherence to treat-
ment or differences in biology or pharmacology may
contribute to this, and have started to become subject
of research within Europe and elsewhere. However,
more research is still needed. Wider approaches to
challenges in European TYA care may include public
and patient involvement, evaluating the impact of spe-
cialist TYA care, and improving TYA content in pro-
fessional training curricula.
Manal Zamzam and Ranin Soliman presented the clin-
ical and research activities for bone sarcomas of the
Children’s Cancer Hospital Egypt (CCHE). An overview
of the paediatric oncology service and auxiliary services,
which capture 1200-1400 new patients with paediatric
cancers each year, were highlighted. The research de-
partment consists of the Research Strategic Business
Unit and units for standards of treatment protocols, epi-
demiology, clinical trials, translational research, biostat-
istics/informatics, a biorepository, a grant office and an
education unit. In addition, CCHE has initiated a fellow-
ship in Paediatric Oncology with Boston Children’s
Hospital. From July 2007, data and samples from 166
osteosarcoma patients have been collected. Five-year
OS for localized osteosarcoma (n = 100) was 76%, 5-yr
EFS 63%.
Biology/genetics: Ewing sarcoma (ES)
Heinrich Kovar (Vienna, Austria) reviewed current in-
sights into the molecular biology of Ewing sarcoma (ES)
and the emerging evidence for the important role of epi-
genetics. He introduced the concept of the disease aris-
ing from a pluripotent mesenchymal stem cell as a
consequence of an EWS/FLI1-induced epigenetic im-
balance leading to differentiation arrest and unrestricted
proliferation. Based on this concept, he postulated that
the sarcoma initiating aberration, the chimeric transcrip-
tion factor, needs to be present at a specific developmental
stage during mesenchyme differentiation at which the epi-
genetic landscape allows EWS/FLI1 to access transform-
ing gene sets. In tumour cells, EWS/FLI1 is found at two
distinct genomic locations, at proximal promoters associ-
ated mostly with gene activation, and distal (>4 kb) regula-
tory elements of predominantly repressed genes. A recent
GWAS study of 401 ES, which were compared with 4,352
controls, revealed an association of ES with nucleotide
polymorphisms on chromosomes 1, 10 and 15. Heinrich
Kovar also reported on European collaborative efforts ap-
plying integrated genomics, including epigenomic profiling,
to identify the mechanism of how these polymorphisms
may affect Ewing sarcoma susceptibility.
Piero Picci discussed the role of miR34a in ES. The
small inhibiting RNA miR-34a is a transcriptional target
of TP53 and induces apoptosis and cell death by silen-
cing, amongst others, CDKs, BCL2, nMyc and SIRT1.
Using qRT-PCR analysis it was shown that high miR-34a
in ES predicted survival and proved to be a significant
prognostic marker in multivariate analysis. qRT-PCR
proved to be more robust as a marker for survival than
In-Situ-Hybridization, and may be useful for patient
stratification at diagnosis in international studies.
David Thomas discussed the International Sarcoma
Kindred Study (ISKS).The ISKS is a unique biological,
epidemiological and clinical study on sarcoma patients
and their families, and a resource created to investigate
the heritable aspects of sarcoma (www.australiansarco-
magroup.org/sarcomakindredstudy). The study started
in Australia, but has partners in Canada, USA, France
and the UK. Of 831 registered patients, more than 100
have a malignant bone tumour. The study is now mov-
ing from single gene studies to complex, next-generation
sequencing studies.
Studies & new hypotheses: Ewing sarcoma
Heribert Juergens gave an overview of the evolution of
ES trials in Europe. In total 4,659 patients have enrolled
in CESS 81, CESS 86, EICESS 92 and EE99. Three-year
EFS improved from 56% to 71%. Systemic treatment
moved from 4 (VACA) to 6 drugs (VAC/IA (E)). Adding
IFO and ETO in addition to interval compression seems
beneficial for non-metastatic ES, but in patients with
metastatic disease or poor response to preoperative chemo-
therapy, the best treatment needs to be defined. The
addition of radiotherapy to surgery seems to have im-
proved local control, irrespective of the response to
chemotherapy. The first results of the EE99 standard
(R1) arm randomisation between cyclophosphamide
and IFO have shown no significant difference in 3y-
EFS or -OS. The R2-arm still is recruiting patients be-
cause the target to answer the randomisation question
has not yet been met. It was concluded that intensive
treatment in ES is essential and combined local treat-
ment is preferable to improve outcome.
Heribert Juergens went on to discuss EWING-2008
(NCT00987636), a study in localised and disseminated
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ES. Randomisation in the R1-arm is between add-on
treatment with zoledronic acid or no add-on treatment
after VAC (females) or VAI (males) maintenance. The
R2-arm is continued from EE99, and a very high-risk arm
(R3) examines the potential benefit of HD-chemotherapy
with stem cell reinfusion added to eight cycles of mainten-
ance chemotherapy. The trial started in 2009, and 313 pa-
tients have been included to date. Other approaches for
future trials in collaboration with the EORTC or INFORM
(Individualized therapy for relapsed malignancies in
childhood adolescents and young adults) were briefly
presented.
Jeremy Whelan and Sandra Strauss presented the ac-
tivity of the EURO-EWING consortium (EEC). The EEC
is an FP7 funded coalition of European study groups and
Sarcoma Patients Euronet (SPAEN), dedicated to im-
prove survival from ES by an integrated programme of
investigator-driven trials that are underpinned by com-
plementary translational research. The activities of the
EEC include a first-line randomised study comparing
VIDE versus an interval- compressed VDC/IE approach
to define the standard of care for neo-adjuvant chemo-
therapy; secondly, a multi-arm randomised trial of 4 sec-
ond-line chemotherapy regimens in recurrent ES, that
serves as a platform for testing new agents; thirdly, to
introduce public and patient involvement in the work of
EEC.
Bass Hassan presented a planned EORTC-EuroSARC
phase-II trial of the dual tyrosine kinase inhibitor for
IGF1R and insulin receptor (IR), linsitinib, in patients
with relapsed or refractory ES (LINES-study). To de-
velop an informative trial, biomarkers will be validated
using exome sequencing and functional imaging of the
effect of linsitinib. This validation is expected to lead to
a better understanding of the mechanism of action of
this dual IGF1R/IR inhibitor.
Conclusions
The meeting provided a thorough update of biological
and clinical studies in both osteosarcoma and ES. Recent
clinical trials have not demonstrated impressive im-
provements in survival, but large collaborations are clearly
feasible and desirable, both clinically as well as scientific-
ally. Preclinical studies have provided a wealth of new
data, requiring renewed bioinformatic analyses. Continued
research is expected to identify new pathways and mecha-
nisms of tumourigenesis, which may then be useful for
the identification of biomarkers and the development of
targeted therapies. However, the complexity of molecular-
genetic events in osteosarcoma and ES has so far impeded
the rapid identification of new treatment targets. Further-
more, translation of pre-clinical models into clinical prac-
tice is anything but simple, and innovative methods of
testing potential drug effects will be needed. Also, limited
interest in developing new agents for these rare cancers
on the part of industry remains a challenge. Nevertheless,
relatively small trials of molecular targeted therapies in
well defined cohorts, validated by reliable biomarkers,
may be a way to open new doors in the treatment of these
tumours.
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